Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Javier A. Pinilla-Ibarz"'
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72e05cfed97bbc9e2e47db93b397aae
https://doi.org/10.1158/1078-0432.c.6528851
https://doi.org/10.1158/1078-0432.c.6528851
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391825ca38ac12df33b7f05e19ba469f
https://doi.org/10.1158/1078-0432.22474643.v1
https://doi.org/10.1158/1078-0432.22474643.v1
Autor:
Javier A. Pinilla-Ibarz, Eduardo M. Sotomayor, John Gordon, John J. Powers, Douglas G. McNeel, Jason A. Dubovsky
Supplementary Data from Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d4b0ed9eb415f0834fb0e5a982bef92
https://doi.org/10.1158/1078-0432.22439800.v1
https://doi.org/10.1158/1078-0432.22439800.v1
Autor:
Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato
Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f28a1d557f9e1d57cd60895ef876dc
https://doi.org/10.1158/1078-0432.22474646.v1
https://doi.org/10.1158/1078-0432.22474646.v1
Autor:
Javier A. Pinilla-Ibarz, Eduardo M. Sotomayor, John Gordon, John J. Powers, Douglas G. McNeel, Jason A. Dubovsky
Purpose: Critical to the success of active immunotherapy against cancer is the identification of immunologically recognized cancer-specific proteins with low tolerogenic potential. Cancer testis antigens (CTA), in particular, fulfill this requirement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c06ebfc4a85c03b1027b09bd134c675e
https://doi.org/10.1158/1078-0432.c.6517216
https://doi.org/10.1158/1078-0432.c.6517216
Autor:
Avery C. Lee, Sai Ravi Pingali, Javier A. Pinilla-Ibarz, Michael L. Atchison, Constantinos Koumenis, Yair Argon, Andrei Thomas-Tikhonenko, Carl De Trez, Chih-Chi Andrew Hu, Chih-Hang Anthony Tang
Publikováno v:
Leukemia. 36(10)
Activation-induced cytidine deaminase (AID) has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it plays in the development and progression of this disease is
Publikováno v:
Cancer Research. 82:142-142
Activation-induced cytidine deaminase (AID) is an enzyme that has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it plays in the development and progression
Autor:
Carly Harro, Jairo Perez-Sanz, Tara Lee Costich, Kyle K Payne, Carmen Maria Anadon Galindo, Ricardo A Chaurio Gonzalez, Subir Biswas, Gunjan Mandal, Kristen E Rigolizzo, Jessica A Mine, Louise C Showe, Kebin Liu, Paulo C Rodriguez, Javier Lee Pinilla-Ibarz, Lubomir Sokol, Jose R Conejo-Garcia
Publikováno v:
The Journal of Immunology. 204:154.8-154.8
Cutaneous T cell lymphoma (CTCL) is a clinically unmet need. Using conditional knockout mice, we found that ablation of the genomic organizer Special AT rich sequence binding protein 1 (Satb1) induces a progressively fatal lymphoma characterized by m